BACE Inhibitor Atabecestat Trial in Pre-Symptomatic Alzheimer's Risk Terminated Early
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
